Cogent Biosciences, Inc. Debt Securities, Available-for-sale, Current
Cogent Biosciences, Inc. (COGT) had Debt Securities, Available-for-sale, Current of $611.13 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Current $611.13M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $625.17M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $588.75M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $265.59M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $611.13M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $625.17M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $588.75M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $265.59M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $110.25M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $119.66M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $188.91M 10-K · filed 2026-02-17 |
| 2024-09-30 | $238.47M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $275.00M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $219.94M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $212.48M 10-K · filed 2025-02-25 |
| 2023-09-30 | $192.23M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $115.08M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $59.57M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $119.39M 10-K · filed 2024-02-26 |
| 2022-09-30 | $148.53M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |